Summit Therapeutics GAAP EPS of -$0.28 beats by $0.01
Seeking Alpha ·
Summit Therapeutics press release ( SMMT ): Q2 GAAP EPS of -$0.28 beats by $0.01 . Aggregate cash and cash equivalents and short-term investments were $690.7 million and $713.4 million at June 30, 2026 and December 31, 2025, respectively. Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It Summit Therapeutics Q2 2026 Earnings Preview Summit updates survival data for Akeso-partnered lung cancer drug
DYAX Investor Sentiment
Bullish (Long) 34% · Bearish (Short) 66%
347 participants
Related News
- Burke & Herbert Financial Services Non-GAAP EPS of $2.03 beats by $0.04, revenue of $106.90M misses by $5.96M
- Stripe in talks to acquire AI startup OpenRouter for ~$10B - report
- Safety Insurance agrees to $1.54B Mapfre buyout deal; shares soar 35% in after-hours
- Ovintiv GAAP EPS of $1.62 misses by $0.49
- U.S. Century Bank GAAP EPS of $0.49 in-line, revenue of $27.95M beats by $1.21M
- Advanced Micro Devices Bets on Helios, Agentic AI to Drive Data Center Growth
